Page last updated: 2024-11-06

n-benzoylpiperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

N-benzoylpiperidine is a chemical compound that has been studied for its potential therapeutic effects. It has been shown to exhibit anticonvulsant activity and has been investigated as a potential treatment for epilepsy. The compound's synthesis typically involves the reaction of piperidine with benzoyl chloride. N-benzoylpiperidine has also been explored for its potential applications in organic synthesis as a building block for other compounds. The compound's pharmacological properties and potential therapeutic benefits have driven its research and development.'

Cross-References

ID SourceID
PubMed CID69892
CHEMBL ID1897277
CHEBI ID188827
SCHEMBL ID243236
MeSH IDM0055285

Synonyms (66)

Synonym
HMS1578B14
smr001530235
protectine i
benzoic acid n-piperidide
nsc-1992
n-benzoylpiperidin
n-benzoyl piperidine
r 162
1-benzoylpiperidine
776-75-0
benzoylpiperidine
n-benzoylpiperidine
p 162
benzoic acid piperidide
mls002637604 ,
benzoic acid, piperidide
nsc1992
piperidine, 1-benzoyl-
lg 20104
.alpha.-repellin
nsc26344
nsc-26344
AC-907/25014313
phenyl(1-piperidyl)methanone
nsc 1992
n-benzoylpiperidin [german]
alpha-repellin
nsc 26344
brn 0136611
einecs 212-280-3
ai3-05550
phenyl(piperidin-1-yl)methanone
STK092213
AKOS000491597
FT-0659564
CHEBI:188827
A839160
NCGC00246771-01
benzoyl piperidine
phenyl-piperidin-1-ylmethanone
b678l9iq0y ,
5-20-02-00450 (beilstein handbook reference)
unii-b678l9iq0y
0ol ,
n-benzoylpiperidine [mi]
methanone, phenyl-1-piperidinyl-
r-162
SCHEMBL243236
4EH4
DTXSID80228265
cambridge id 5172602
CHEMBL1897277
B5512
mfcd00023702
benzoylpiperidin
F0808-1081
phenyl-piperidin-1-yl-methanone
protectine i;alpha-repellin
Q27274423
D89138
BS-44008
SB41089
protectine i;-repellin
EN300-1265370
CS-0014481
phenyl(piperidino)methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
N-acylpiperidine
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency63.09570.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)1,534.0000292.00001,327.00003,471.0000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2013Nature chemistry, Jan, Volume: 5, Issue:1
Natural-product-derived fragments for fragment-based ligand discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's0 (0.00)18.2507
2000's2 (14.29)29.6817
2010's7 (50.00)24.3611
2020's4 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.63 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]